## 2024 AAPS PharmSci 360 - Poster Abstract Tracks (Subtracks) | Primary Topics | Keywords = (Review Groups)

There are five robust tracks covering all aspects of the pharmaceutical sciences. Three tracks are divided into two subtracks with Biomolecular and Chemical focuses. The Tracks Discovery and Basic Research and Preclinical, Clinical, and Translational Sciences, are not split into subtracks.

IMPORTANT NOTE: In the submission site the structure below, Track (Subtrack), Primary Topic, and Keywords, are referred to as Review Groups. Screeners, please select all Review Groups that apply to your expertise.

## **Review Group Selection Process**

- 1. Select the Track-Subtrack that best fits your research. (see below)
- \* Discovery and Basic Research
- \* Preclinical, Clinical, and Translational Sciences
- \* Bioanalytics
- \* Manufacturing and Analytical Characterization
- \* Formulation and Delivery
- 2. Select the Subtrack (Biomolecular or Chemical). Doesn't apply to the Discovery and Basic Research and Preclinical, Clinical, and Translational Sciences tracks.
- 3. Select the Primary Topic that best fits your research.
- 4. From your Primary Topic, select the best Keywords for your research. If no listed Keywords fits your research, select 'Other'. (Note: In some instances there are no Keywords.)

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
		New Applications of Existing Technology
Discovery and Basic Research		New Approaches
		New Technology
		Biomarkers
		Cell Therapy CAR-T, STEM Cell, Other
		Cellular and Molecular Pathways
		Gene Therapy
		Immunogenicity
		In Silico
		In Vitro
Discovery and Basic Research	Piology	In Vivo
Discovery and basic Research	Biology	Metabolizing Enzymes
		Omics
		Protein Binding
		Protein/Gene Engineering and Expression
		Receptor/Target Interactions
		Target Identification
		Transporter
		Other
		Combinatorial Chemistry
		Fragment Based Design
		In Silico Based Design
		Natural Products
Discovery and Basic Research		Novel Drug Modality
Discovery and basic research	·	Peptides and other Large Molecules
		Rational Drug Design
		Small Molecules
		Structure Activity Relationship
		Synthetic Chemistry
		Drug Delivery Novel Systems

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
		Drug Delivery Ocular
		Drug Delivery Transdermal
		Drug Transport and Transporters
Discovery and Basic Research	Pharmaceutics	Modeling and Simulation: New Approaches
		Molecular Biopharmaceutics
		Novel Drug Modality
		Pharmaceutical Polymers
		Pharmacokinetics
		Behavioral Pharmacology
		Bioanalytical
		Biomarkers
		Cell Death and Differentiation
		DNA Damage and Repair
		Drug Abuse
		Drug-Drug Interactions
		Epigenetics and Epigenetic Therapy
		Experimental Therapeutics
		Gene Therapy
		Immunotherapy and Immunopharmacology
Discovery and Basic Research	Pharmacology	Natural Products
		Neuropharmacology
		Omics (genomics, metabolomics, epigenomics, proteomics)
		Oncology (hematologic malignancies)
		Oncology (solid tumors)
		Orphan Drugs and Rare Diseases
		Pharmacokinetics
		Quantitative Pharmacology
		Signal Transduction
		Systems Pharmacology
		Toxicology
		Vaccines
		Biotransformation (In Vitro and In Vivo)
		High Throughput Assays
		Metabolite Identification and Characterization
		Metabolizing Enzymes Biotransformation (In Vitro and In Vivo)
		Novel Drug Modality/Novel Drug Delivery
Preclinical, Clinical, and Translational Sciences	ADME	Optimization of Protein Design
Frechineal, Chineal, and Translational Sciences	ADME	Payload-Linker Identification/Optimization
		Permeability, Distribution, and Site of Action
		Pharmacokinetics
		Screening Tools for Candidate Optimization
		Transporters Biotransformation (In Vitro and In Vivo)
		Other
Preclinical, Clinical, and Translational Sciences		Clinical Qualification
	Biomarkers	Disease Heterogeneity Assessments
		Endpoints (Surrogate , Primary, Secondary, Exploratory)
		High Content Data Analysis
		Novel Biomarkers
		Observational/Epidemiology Studies
		Patient Selection
		Bayesian Methods

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
		Clinical Study Design
		Regulatory Recommendations
Preclinical, Clinical, and Translational Sciences	Biostatistical Methodologies	Statistical Analysis Models
		Statistical Reporting
		Tools/Software
		Other
		Designs and Methodology (Including QdB and RBM)
		Dosing Strategies
		Drug Interaction Studies
		Ethics in Clinical Trials
		Ex-US and Multi-national Studies
Preclinical, Clinical, and Translational Sciences	Clinical Trials	Monitoring
		Patient Stratification
		Real World Evidence
		Regulatory Guidance
		Special Population Studies
		Other
		Clinical Relevance
		Factor in Species Selection
Provided Official and Translational October	1	Immunogenicity Risk Assessment
Preclinical, Clinical, and Translational Sciences	Immunogenicity	Impact on Exposure
		Impact on Safety Assessment
		Integrated Summary of Immunogenicity
		Post-Marketing Surveillance and REMS
		ADCs
		Alternative Scaffold
		Bispecifics, Trispecifics and Higher Order Complexities
		CAR-T and Other Modified Cell Lines
		Cell-Based Therapy
		Encapsulated Drugs (Lipid, Nanoparticle, and Viral Vectors)
Preclinical, Clinical, and Translational Sciences	Modalities	Multispecific Antibodies
		Nanoparticle-Based
		Oligos, RNAs, and Locked Nucleic Acids
		PROTACs and Similar Molecular Glues
		Small Molecules
		Vaccines
		Other
		Absorption Modeling
		Advanced Modeling Approaches
		Big Data and Artificial Intelligence
		Comparator Modeling
		Dose Project/Selection and Justification
		Drug interactions
		•
		Imaging Based Approach In Vivo-In Vitro Correlation (IVIVC) Modeling
Preclinical, Clinical, and Translational Sciences	Modeling and Simulation	Maternal/Fetal PK Model
		Other Special Populations
		Pediatric Model
		PK/PD Modeling
		Population PK Modeling
		Quantitative Systems Pharmacology (QSP)

PK/PD Safety Other  Adaptive and Accelerated Designs Bioequivalence Biosimilars Diseased Patient Population Studies Drug-Drug Interaction (DDI) First-Time-in-Human (FTIH) Food Effect Geriatric Organ Impairment Other Special Populations Pediatric Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/QTc (TQT) Other Ex Vivo	TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
Preclinical, Clinical, and Translational Sciences  OMICS			
Other Commonies Omnomies Omnomies Metabolomies Preclinical, Clinical, and Translational Sciences  OMICS  Officer Clinical Study Reports (CSRs) Clinical Studies and Molecular Studies Company Studies Compan			
Preclinical, Clinical, and Translational Sciences  OMICS  Genomics  Metaboborides  Protomics  Clinical Study Reports (CSRs)  Clinical Authority Interaction/Retrings  Labeling  Regulatory Filings and Submissions  Setty  Other  Culturiar and Molecular Toxicology  Other			
Preclinical, Clinical, and Translational Sciences  OMICS  Metabohomics Proteomics Other  Clinical Study Reports (CSRs) Clinical Study Reports (CSRs) Clinical Trial Protocols Outs Standards and Wangement (Including CDISC) Harmonization and Guidence Documents Hostin Auditory Herizachomy Meterings Labelling Regulatory Guidance/Submissions  State  Precinical, Clinical, and Translational Sciences  Safety  Cultura and Molecular Toxicology De-Inking Strategies Genetic Toxicity IND Enabling Studies Genetic Toxicity IND Enabling Studies Genetic Toxicity Screening Toxicity Studies Other  Precinical, Clinical, and Translational Sciences  Translation  Precinical, Clinical, and Translational Sciences  Translation  Translation  Precinical, Clinical, and Translational Sciences  Translation  Translation  Translation  Translation  Translation Selection Profile Internation In			Other
Proteomics Other Other Other Clinical Study Reports (CSRa) Clinical Trial Protocols Data Standards and Management (Including CDISC) Harmorization and Quidance Documents Health Authority Interactions/Meetings Labeling Regulatory Filings and Submissions Safety Clinical Clinical, and Translational Sciences  Safety  Preclinical, Clinical, and Translational Sciences  Safety  Safety De-risking Strategies Center Toxicity Immunic-toxicity Destinated Toxicity Screening Toxicity Studies Outper Drips Dury Interaction (DN) Formulation Selection Patient Selection Pipp D Safety Other  Preclinical, Clinical, and Translational Sciences  Type of Human Studies  Type of Human Studies  Drug Dury Interaction (DN) First-Time-in-Human (Filis) Food Effect Cogniting Drug Interaction (DN) First-Time-in-Human (Filis) Food Effect Cognition Drug Interaction (DN) First-Time-in-Human (Filis) First-Time			
Preclinical, Clinical, and Translational Sciences  Regulatory Guidance/Submissions  Regulatory Guidance/Submissions  Regulatory Guidance/Submissions  Regulatory Guidance/Submissions  Regulatory Guidance/Submissions  Regulatory Finite and Manapenent (including CDISC) Harmonization and Guidance Decuments Health Authority Interactions/Releating Legulatory Finite and Submissions Safety  Ober Interactions/Releating Designation of Control of	Preclinical Clinical and Translational Sciences	OMICS	Metabolomics
Clinical Study Reports (CSR) Clinical Trial Protocols Data Standards and Management (Including CDISC) Harmorization and Studiance Documents Health Authority Interactions/Meetings Labeling Regulatory Filings and Submissions  Safety Other  Cellular and Molecular Toxicology Other (Including CDISC) De-risking Strategies Genetic Toxicity Immuno-toxicity In Denabring Studies Mechanistic Toxicity Screening Toxicity Studies Other  Preclinical, Clinical, and Translational Sciences  Translation  Translational Sciences  Translation  Translation  Translational Sciences  Translation  Translational Sciences  Translation  Translation  Translational Sciences  Translati			
Preclinical, Clinical, and Translational Sciences  Regulatory Guidance/Submissions  Regulatory Guidance/Submissions  Regulatory Guidance/Submissions  Regulatory Guidance/Submissions  Regulatory Guidance/Submissions  Regulatory Filings and Submissions  Safety  Cellular and Modecular Toxicology  Toxicology  Cellular and Modecular Toxicology  Cellular and Modecular Toxicology  Cellular and Modecular Toxicology  College Cellular			
Preclinical, Clinical, and Translational Sciences  Regulatory Guidance/Submissions  Regulatory Guidance/Submissions  Regulatory Guidance/Submissions  Regulatory Filings and Submissions  Regulatory Filings and S			
Preclinical, Clinical, and Translational Sciences  Regulatory Guidance/Submissions  Harmonization and Guidance Documents Health Authority Interactions/Desetings Labeling Regulatory Filings and Submissions Safety Other  Cellular and Molecular Toxicology Deviating Strategies Genetic Toxicity Immuno-toxicity Immuno-toxi			
Preclinical, Clinical, and Translational Sciences  Regulatory Guidance/Submissions    Health Authority Interactions/Meetings			
Labeling Regulatory Filings and Submissions Safety Other Cultura and Molecular Toxicology De-risking Strategies Genetic Toxicity Immuno-toxicity Immuno-toxicity Immuno-toxicity Immuno-toxicity Immuno-toxicity Serening Toxicity Studies Mechanistic Toxicity Serening Toxicity Studies Other  Drug-Drug Interaction (DDI) Formulation Selection Human Ptw and Dose Projections Patient Selection PMPD Safety Other Adaptive and Accelerated Designs Biosquivalence Biosimilars Diseased Patient Population Studies Drug-Drug Interaction (DDI) First-Time-in-Human FTIH) Food Effect Geriatric Organ Impairment Other Special Populations Peciatric Pregaint Vomen Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough Or/Or/Or (TGT) Other			
Regulatory Filings and Submissions Safety Other  Cellular and Molecular Toxicology De-risking Strategies Genetic Toxicity Immune-toxicity Immune-toxicity Immune-toxicity RID Enabling Strategies Genetic Toxicity RID Enabling Strategies Other  Other  Preclinical, Clinical, and Translational Sciences  Translation  Preclinical, Clinical, and Translational Sciences  Translation  Translational Sciences  Translation  Preclinical, Clinical, and Translational Sciences  Translation  Translational Sciences  Translation  Preclinical, Clinical, and Translational Sciences  Translation  Translational Sciences  Translation  Preclinical, Clinical, and Translational Sciences  Translation  Translational Sciences  Type of Human Studies  Drug-Drug Interaction CDID First-Time-in-Human (FTIH) Food Effect  Organ Impairment  Organ Impairment  Organ Impairment  Organ Impairment  Organ Impairment  Pregnant Womon  Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies Balance, Microdose and ADME Registrationa	Preclinical, Clinical, and Translational Sciences	Regulatory Guidance/Submissions	Health Authority Interactions/Meetings
Safety Cellular and Molecular Toxicology  Preclinical, Clinical, and Translational Sciences  Safety  S			
Other  Cellutar and Molecular Toxicology De-risking Strategies Genetic Toxicity Immun-oxicity Immun-oxicity IND Enabling Studies Mechanistic Toxicity Screening Toxicity Studies Other  Preclinical, Clinical, and Translational Sciences  Translation  Tran			Regulatory Filings and Submissions
Cellular and Molecular Toxicotogy De-risking Strategies Genetic Toxicity Immuno-toxicity IND Enabling Studies Mechaniste Toxicity Screening Toxicity Studies Other Orug-Drug Interaction (DDI) Formulation Selection Human PK and Dose Projections Patient Selection PKPD Safety Other Adaptive and Accelerated Designs Bioequivalence Biosimilars Diseased Patient Population Studies Drug-Drug Interaction (DDI) First-Time-in-Human (FTIH) Food Effect Geriatric Organisment Other Special Populations Pediatric Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough GTGTC (TGT) Other EX Vivo			Safety
Preclinical, Clinical, and Translational Sciences  Safety  Safety  Safety  Safety  De-risking Strategies Genotic Toxicity Immuno-toxicity Immu			
Preclinical, Clinical, and Translational Sciences  Safety  Safety  Drug-Drug Interaction (DDI) Formulation Selection Human PK and Dose Projections Patient Selection Human PK and Dose Projections Patient Selection PI/PD Safety Other  Adaptive and Accelerated Designs Bioequivalence Biosimilars Diseased Patient Population Studies Drug-Drug Interaction (DDI) Formulation Selection PI/PD Safety Other Adaptive and Accelerated Designs Bioequivalence Biosimilars Diseased Patient Population Studies Drug-Drug Interaction (DDI) First-Time-in-Human (Fifth) Food Effect Geriatric Organ Impairment Other Special Populations Pediatric Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/OTC (TQT) Other			Cellular and Molecular Toxicology
Preclinical, Clinical, and Translational Sciences  Safety  Immuno-toxicity IND Enabling Studies Mechanistic Toxicity Screening Toxicity Studies Other  Drug-Drug Interaction (DDI) Formulation Selection Human PK and Dose Projections Patient Selection PIVPD Safety Other  Adaptive and Accelerated Designs Bioequivalence Biosimilars Diseased Patient Population Studies Drug-Drug Interaction (DDI) First-Time-in-Human (FTH) Food Effect Geriatric Organ Impairment Other Special Populations Pediatric Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QTQTC (TQTT) Other  Ex Vivo			De-risking Strategies
Preclinical, Clinical, and Translational Sciences  Preclinical, Clinical, and Translational Sciences  Translation  Transla			Genetic Toxicity
Preclinical, Clinical, and Translational Sciences  Translation  Transl	Preclinical Clinical and Translational Sciences	Safety	Immuno-toxicity
Preclinical, Clinical, and Translational Sciences  Translation  Patient Selection  Adaptive and Accelerated Designs  Bioequivalence  Biosimilars  Diseased Patient Population Studies  Drug-Drug Interaction (DDI)  First-Time-in-Human (FTIH)  Food Effect  Geriatric  Organ Impairment  Other Special Populations  Pediatric  Pregnant Women  Radio-Labeled Mass Balance, Microdose and ADME  Registrational Studies and Strategies  Relative and Absolute Bioavailability  Thorough QT/QTc (TQT)  Other  Ex Vivo	Trechnical, offical, and Translational ociences	Jaiety	IND Enabling Studies
Preclinical, Clinical, and Translational Sciences  Translation  Transl			Mechanistic Toxicity
Preclinical, Clinical, and Translational Sciences  Translation  Transl			Screening Toxicity Studies
Preclinical, Clinical, and Translational Sciences  Translation  Transl			Other
Preclinical, Clinical, and Translational Sciences  Translation  Transl			Drug-Drug Interaction (DDI)
Preclinical, Clinical, and Translational Sciences  Translation  PRI/PD  Safety Other  Adaptive and Accelerated Designs Bioequivalence Biosimilars Diseased Patient Population Studies Drug-Drug Interaction (DDI) First-Time-in-Human (FTiH) Food Effect Geriatric Organ Impairment Other Special Populations Prediatric Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/QTc (TQT) Other  Ex Vivo			Formulation Selection
PK/PD Safety Other  Adaptive and Accelerated Designs Bioequivalence Biosimilars Diseased Patient Population Studies Drug-Drug Interaction (DDI) First-Time-in-Human (FTIH) Food Effect Geriatric Organ Impairment Other Special Populations Pediatric Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/QTc (TQT) Other Ex Vivo			Human PK and Dose Projections
Safety Other  Adaptive and Accelerated Designs Bioequivalence Biosimilars Diseased Patient Population Studies Drug-Drug Interaction (DDI) First-Time-in-Human (FTIH) Food Effect Geriatric Organ Impairment Other Special Populations Pediatric Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/QTc (TQT) Other Ex Vivo	Preclinical, Clinical, and Translational Sciences	Translation	Patient Selection
Other  Adaptive and Accelerated Designs Bioequivalence Biosimilars Diseased Patient Population Studies Drug-Drug Interaction (DDI) First-Time-in-Human (FTIH) Food Effect Geriatric Organ Impairment Other Special Populations Pediatric Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/QTc (TQT) Other Ex Vivo			PK/PD
Adaptive and Accelerated Designs Bioequivalence Biosimilars Diseased Patient Population Studies Drug-Drug Interaction (DDI) First-Time-in-Human (FTIH) Food Effect Geriatric Organ Impairment Other Special Populations Pediatric Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/QTC (TQT) Other Ex Vivo			Safety
Bioequivalence Biosimilars Diseased Patient Population Studies Drug-Drug Interaction (DDI) First-Time-in-Human (FTIH) Food Effect Geriatric Organ Impairment Other Special Populations Pediatric Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/QTC (TQT) Other			Other
Biosimilars  Diseased Patient Population Studies  Drug-Drug Interaction (DDI)  First-Time-in-Human (FTIH)  Food Effect  Geriatric  Organ Impairment  Other Special Populations  Prediatric  Pregnant Women  Radio-Labeled Mass Balance, Microdose and ADME  Registrational Studies and Strategies  Relative and Absolute Bioavailability  Thorough QT/QTc (TQT)  Other  Ex Vivo			Adaptive and Accelerated Designs
Diseased Patient Population Studies Drug-Drug Interaction (DDI) First-Time-in-Human (FTIH) Food Effect Geriatric Organ Impairment Other Special Populations Pediatric Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/QTc (TQT) Other Ex Vivo			Bioequivalence
Preclinical, Clinical, and Translational Sciences  Type of Human Studies  Organ Impairment  Other Special Populations  Pediatric  Pregnant Women  Radio-Labeled Mass Balance, Microdose and ADME  Registrational Studies and Strategies  Relative and Absolute Bioavailability  Thorough QT/QTc (TQT)  Other  Ex Vivo			Biosimilars
Preclinical, Clinical, and Translational Sciences  Type of Human Studies  Organ Impairment  Other Special Populations  Pediatric  Pregnant Women  Radio-Labeled Mass Balance, Microdose and ADME  Registrational Studies and Strategies  Relative and Absolute Bioavailability  Thorough QT/QTc (TQT)  Other  Ex Vivo			Diseased Patient Population Studies
Preclinical, Clinical, and Translational Sciences  Type of Human Studies  Organ Impairment Other Special Populations Pediatric Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/QTc (TQT) Other Ex Vivo			Drug-Drug Interaction (DDI)
Preclinical, Clinical, and Translational Sciences  Type of Human Studies  Organ Impairment Other Special Populations Pediatric Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/QTc (TQT) Other Ex Vivo			First-Time-in-Human (FTIH)
Preclinical, Clinical, and Translational Sciences  Type of Human Studies  Organ Impairment Other Special Populations Pediatric Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/QTc (TQT) Other Ex Vivo			
Other Special Populations Pediatric Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/QTc (TQT) Other Ex Vivo			Geriatric
Pediatric Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/QTc (TQT) Other Ex Vivo	Preclinical, Clinical, and Translational Sciences	Type of Human Studies	Organ Impairment
Pediatric Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/QTc (TQT) Other Ex Vivo			
Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/QTc (TQT) Other Ex Vivo			
Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/QTc (TQT) Other Ex Vivo			
Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/QTc (TQT) Other Ex Vivo			
Relative and Absolute Bioavailability Thorough QT/QTc (TQT) Other Ex Vivo			
Thorough QT/QTc (TQT) Other Ex Vivo			
Other Ex Vivo			
Ex Vivo			Other
Pigalarias Pigulorogiai IAlaria Diability III VIII C	Bioanalytics - Biomolecular	Analyte Stability	In Vitro

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
		Solution
Bioanalytics - Biomolecular	Bioanalytical Innovations and Applications	n/a
Bioanalytics - Biomolecular	Bioanalytical Risk Assessment and Strategy	n/a
		Biomarker/Pharmacodynamic Measurement
		Clinical Qualification
		Diagnostic Development (including companion diagnostics)
		Disease Heterogeneity Assessments
		Exosome
		Flow Cytometry Methods
		High Content Data Analysis
		Hybrid Methods (e.g. IP/LCMS)
		Imaging Methods
Bioanalytics - Biomolecular	Biomarker Quantification	Ligand Binding Assay (LBA) Methods
		Mass Spectrometry (LC-MS) Methods
		New Matrices
		New Modalities
		OMICs
		PCR Methods
		Preanalytical Variables
		Single-Cell-Based Biomarkers
		Target Engagement/Receptor Occupancy
		Vaccines
		Endogenous Homologs Quantification
		Flow Cytometry Methods
		Hybrid Methods (e.g. IP/LCMS)
		Imaging Methods
Bioanalytics - Biomolecular	B 0 000 0	Ligand Binding Assay (LBA) Methods
	Drug Quantification	Mass Spectrometry (LC-MS) Methods
		PCR Methods
		Other Methods/Techniques
		Therapeutic Drug Monitoring
		Post-marketing Commitment
		Surrogate Analyte
		Binding Antibody Methods
		Cell-Based Methodologies
Bioanalytics - Biomolecular	Immunogenicity	Neutralizing Antibody Methods
		Immunogenicity Risk Assessments
		Immunogenicity Prediction
		ADC Metabolism
		Evaluation of In Vivo Biotransformation
Bioanalytics - Biomolecular	In Vivo and Ex Vivo Biotransformation	Impact of Biotransformation on Immunogenicity
		Impact of Biotransformation on PK
		Molecule Variants Quantification Ex Vivo
		Collaboration with other Partners (Co-development)
Bioanalytics - Biomolecular	Life Code Management (17)	Data Management
	Life Cycle Management of Bioanalytical Methods	General Life Cycle Management
		Methods Transfer and CRO Management
		ADCs
		Alternative Scaffold
		CAR-T
		Cell-Based Therapy
	1	Gen-pased Therapy

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
Bioanalytics - Biomolecular	Novel Modalities	Encapsulated Drugs (Lipid, Nanoparticle, etc.)
bioanalytics - biomoleculai	Novel modalities	Multi-specific Antibodies
		Nanoparticle Based Modalities
		Oligos, RNAs, and Locked Nucleic Acids
		Viral Vectors
		Other
		Characterization and Quality Control
Bioanalytics - Biomolecular	Reagents and Reference Standards	Life Cycle Management
		Stability
		Biomarkers
		Drug (and Metabolites)
		GCP/GLP Compliance for Bioanalytical Labs
Bioanalytics - Biomolecular	Regulations (BMV/GLP/GCP/CLIA)	General Topics
		ICH and Harmonization
		Immunogenicity and Risk Assessment
		Samples and Reagent Stability
		Bioanalytical Documentation and Reports
		Biorepositories
		Informed Consent
Bioanalytics - Biomolecular	Samples and Laboratory Management	Laboratory Information Management System (LIMS)
		Patient-Centric Sampling (microsampling and dried blood spots)
		Post-Collection Sample Condition and Record Management
		Binding Antibody Methods
Bioanalytics - Biomolecular	Vaccines	Cell-Based Methodologies
		Correlates of Protection
		Neutralizing Antibody Methods
		Ex Vivo
Bioanalytics - Chemical	Analyte Stability	In Vitro
		Solution
Bioanalytics - Chemical	Bioanalytical Innovations and Applications	n/a
Bioanalytics - Chemical	Bioanalytical Risk Assessment and Strategy	n/a
		Biomarker/Pharmacodynamic Measurement
		Clinical Qualification
		Diagnostic Development (including companion diagnostics)
		Disease Heterogeneity Assessments
		Exosome
		Flow Cytometry Methods
		High Content Data Analysis
		Hybrid Methods (e.g. IP/LCMS)
		Imaging Methods
Bioanalytics - Chemical	Biomarker Quantification	Ligand Binding Assay (LBA) Methods
		Mass Spectrometry (LC-MS) Methods
		New Matrices
		New Modalities
		OMICs
		PCR Methods
		Preanalytical Variables
		Single-Cell-Based Biomarkers
		Target Engagement/Receptor Occupancy
		Endogenous Homologs Quantification
		Flow Cytometry Methods

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
		Hybrid Methods (e.g. IP/LCMS)
		Imaging Methods
		Ligand Binding Assay (LBA) Methods
Bioanalytics - Chemical	Drug Quantification	Mass Spectrometry (LC-MS) Methods
		PCR Methods
		Other Methods/Techniques
		Therapeutic Drug Monitoring
		Post-marketing Commitment
		Surrogate Analyte
		Binding Antibody Methods
		Cell-Based Methodologies
Bioanalytics - Chemical	Immunogenicity	Immunogenicity Prediction
		Immunogenicity Risk Assessments
		Neutralizing Antibody Methods
		ADC Metabolism
		CYP450 Assessment
		Evaluation of In Vivo Biotransformation
Bioanalytics - Chemical	In Vivo and Ex Vivo Biotransformation	Impact of Biotransformation on Immunogenicity
		Impact of Biotransformation on PK
		Metabolite Quantification
		Collaboration with other Partners (Co-development)
Bioanalytics - Chemical	Life Cycle Management of Bioanalytical Methods	Data Management
		General Life Cycle Management
		Methods Transfer and CRO Management
		ADCs
		Alternative Scaffold
		CAR-T
		Cell-Based Therapy
Bioanalytics - Chemical	Novel Modalities	Encapsulated Drugs (Lipid, Nanoparticle, etc.)
bloanarytics - offerfical	Novel modalities	Multi-specific Antibodies
		Nanoparticle Based Modalities
		Oligos, RNAs, and Locked Nucleic Acids
		Viral Vectors
		Other
		Characterization and Quality Control
Bioanalytics - Chemical	Reagents and Reference Standards	Life Cycle Management
		Stability
		Biomarkers
		Drug (and Metabolites)
		GCP/GLP Compliance for Bioanalytical Labs
Bioanalytics - Chemical	Regulations (BMV/GLP/GCP/CLIA)	General Topics
		ICH and Harmonization
		Immunogenicity and Risk Assessment
		Samples and Reagent Stability
		Bioanalytical Documentation and Reports
		Biorepositories
Bioanalytics - Chemical	Samples and Laboratory Management	Informed Consent
		Laboratory Information Management System (LIMS)
		Patient-Centric Sampling (microsampling and dried blood spots)
		Post-Collection Sample Condition and Record Management
I		Combination Products

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
		Excipients
		Immunogenicity
		Impurities
		Modality Specific Methods - Cell Therapy
		Modality Specific Methods - Free Oligonucleotide
		Modality Specific Methods - Gene Therapy
Manufacturing and Analytical Characterization - Biomolecular	Analytical	Modality Specific Methods - Protein
		Modality Specific Methods - Vaccine/Tolerance Induction
		Modality Specific Methods - Other
		New Technology
		Potency/Bioassay
		(Sub)visible Particles
		Other
		Computer Validation
Manufacturing and Analytical Characterization - Biomolecular	Automation	Other
Manufacturing and Analytical Characterization. Biomelacular	Discipling Manufacturing	Biosimilarity Assessment
Manufacturing and Analytical Characterization - Biomolecular	Biosimilar Manufacturing	Patent Protection
		Other
		Aseptic Technologies - Mixing, Sterilization, and Filling
		Cell Therapies
		Freezing and Thawing
		Immunogenicity and Critical Quality Attributes
		Lyophilization and Drying Technologies
		Manufacturing and Assembly of Drug/Device Combinations
		Manufacturing of Drug Delivery Systems
		Primary Packaging - Container Closure Integrity
		Primary Packaging - Syringes
Manufacturing and Analytical Characterization Biamalacular	Drug Braduet Manufacturing and Davidsonment	Primary Packaging - Vials
Manufacturing and Analytical Characterization - Biomolecular	Drug Product Manufacturing and Development	Primary Packaging - Other
		Process Characterization and Optimization
		Protein Aggregation and Degradants
		Secondary Packaging
		Storage Considerations
		Vaccines
		Viral and Non-viral Vectors and Gene Therapy
		Visible and Subvisible Particles
		Visual Inspection
		Other
		API Packaging and Storage
		Cell Line Development
		Cell Therapies
		Clonality Assessments
Manufacturing and Analytical Characterization - Biomolecular		Expression Systems - Cellular and Cell-Free
		-
		Genetic and Cell Line Engineering
		Mammalian Cell Culture
	Drug Substance Manufacturing and Development	Media Development
		Microbial/Yeast Fermentation
		Process Optimization and Intensification
		Protein Aggregation during Processing and Immunogenicity
		Purification and Virus Removal
		Vaccines

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
		Virus Safety/Removal
		Viral and Non-viral Vectors and Gene Therapy
		Other
		Change Control
		CMO Management
		Drug Master Files
		Drug Substance and Drug Product Shipment
		Electronic Records
		Handling Control Substances (DEA)
		Inspections and GMP
Manufacturing and Analytical Characterization - Biomolecular	General Aspects and Strategies	Lean Manufacturing/Six Sigma/Operational Excellence
		Life Cycle Management
		Manufacturing Economics
		Materials Management and Warehousing
		Regulatory Strategy
		Supply Chain
		Other
		Containment and Isolators
		High-Potent Drug Manufacturing
Manufacturing and Analytical Characterization - Biomolecular	Health, Safety, and Environment	OEL and PDE
		Other
		For Use in Drug Product Manufacture
Manufacturing and Analytical Characterization - Biomolecular	Innovative/Novel Processing Technologies and Concepts	For Use in Drug Substance Manufacture
		Other
		For Use in Drug Product Manufacture
Manufacturing and Analytical Characterization - Biomolecular	Integrated and Continuous Processing and Manufacturing	For Use in Drug Substance Manufacture
		Other
		Blinding of Comparator Drugs
Manufacturing and Analytical Characterization - Biomolecular	Manufacture of Clinical Supplies	Phase Appropriate GMP
manufacturing and Analytical Characterization - Biomolecular	manufacture of officer oupplies	Speed to Patient
		Other
		Facility Design
		Legacy Facility Innovation/Renovation
		Media
		Media Fills
Manufacturing and Analytical Characterization - Biomolecular	Plant Engineering and Maintenance	Media/Buffer Preparation and Fluid Management
	. tan Inginoring and manner	Modeling and Scheduling Multiproduct Batch Plants
		Modular Manufacturing
		Plant Incident Investigations
		Other
		Cleaning Validation
Manufacturing and Analytical Characterization - Biomolecular		Control of Impurity Formation
		In-Process Controls
		Process Analytical Technology and Parametric/Real-Time Release
		Process Modeling and Simulations
	Process Design and Controls	Process Validation/Continuous Process Validation
		QbD and Assessment of Process Parameters
		Scale-Up/Process Transfers
		Statistical Process Controls and Six Sigma
		Use of Prior Knowledge and Risk-Based Approaches
		Other

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
		For Use in Drug Product Manufacture
Manufacturing and Analytical Characterization - Biomolecular	Single-Use and Disposable Systems	For Use in Drug Substance Manufacture
Manufacturing and Analytical Characterization - Biomolecular	Single-ose and Disposable Systems	Leachables and Extractables
		Other
		Continuous/Real-Time Release
		Drug Release Measurement - Biorelevant Dissolution
		Drug Release Measurement - Cascade Impaction
		Drug Release Measurement - Dissolution
		Drug Release Measurement - Forms
		Drug Release Measurement - Other
		Excipients
		Impurities and Degradation - Forced Degradation
		Impurities and Degradation - Impurity Quantitation
Manufacturing and Analytical Characterization - Chemical	Analytical	Impurities and Degradation - In Silico Predecision of Stability
		Impurities and Degradation - Other
		Method Development Strategies
		Model Maintenance
		New Analytical Technologies
		Physical Characterization Techniques
		Process Analytical Technology and Continuous Release Testing
		Real Time Release testing
		Other
Manufacturing and Analytical Characterization - Chemical	Automation	Computer Validation
		Other
		Aseptic Technologies and Sterilization - Filling
		Aseptic Technologies and Sterilization - Filtration
		Aseptic Technologies and Sterilization - Mixing
		Aseptic Technologies and Sterilization - Other
		Bulk Packaging
		Freezing and Thawing
		Immunogenicity and Critical Quality Attributes
		Liquids Manufacture - Oral and Topical Liquids
		Liquids Manufacture - Other
		Lyophilization and Drying Technologies
		Manufacturing and Assembly of Drug/Device Combinations
		Manufacturing of Aerosols and DPI
		Manufacturing of Drug Delivery Systems
		Primary Packaging - Blisters
		Primary Packaging - Bottles
Manufacturing and Analytical Characterization - Chemical	Drug Product Manufacturing and Development	Primary Packaging - Container Closure Integrity
manufacturing and Analytical Characterization - Chemical	Drug Froduct Mandracturing and Development	
		Process Optimization
		Secondary Packaging
		Semi-solids Manufacture - Cremes
		Semi-solids Manufacture - Liposomes, Solid Lipid Nanoparticles
		Semi-solids Manufacture - Other
		Shipping Studies
		Solids Manufacture - Capsules
		Solids Manufacture - Drug Product Intermediates
		Solids Manufacture - Mini-tablets
		Solids Manufacture - Powders
		Solius Marialacture - Powders

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
		Solids Manufacture - Other
		Storage Considerations
		Visual Inspection
		Other
		API Kilo Lab
		API Packaging and Storage
		Control of Impurity Formation
		Crystal Structure/Polymorph Screening
		Crystallization Development
		Filtration
		Genotoxic Impurities
Manufacturing and Analytical Characterization - Chemical	Drug Substance Manufacturing and Development	Immunogenicity and Critical Quality Attributes
		Milling and Micronization Technologies
		Particle Size Control
		Process Chromatography
		Process Optimization
		Purification
		Other
		Change Control
		CMO Management
		Drug Master Files
		Drug Substance and Drug Product Shipment
		Electronic Records
		Handling Control Substances (DEA)
Manufacturing and Analytical Characterization - Chemical	General Aspects and Strategies	Inspections and GMP
Manufacturing and Analytical Characterization - Chemical	General Aspects and Strategies	Lean Manufacturing/Six Sigma/Operational Excellence
		Life Cycle Management
		Manufacturing Economics
		Materials Management and Warehousing
		Regulatory Strategy
		Supply Chain
		Other
		Patent Protection
Manufacturing and Analytical Characterization - Chemical	Generic Manufacturing	Pharmaceutical Equivalence Assessment
	3	Other
		Containment and Isolators
		Explosion Protection
		Green Chemistry
Manufacturing and Analytical Characterization - Chemical	Health, Safety, and Environment	High-Potent Drug Manufacturing
manufacturing and Analytical Gharacterization - Ghemical	neatti, Salety, and Environment	OEL and PDE
		Solvent Recovery
		·
		Other
Manufacturing and Analytical Characteristics Characterist	lum acception (Marcal Dua accession Technical accession 100)	For Use in Drug Product Manufacture
Manufacturing and Analytical Characterization - Chemical	Innovative/Novel Processing Technologies and Concepts	For Use in Drug Substance Manufacture
		Other
		For Use in Drug Product Manufacture
Manufacturing and Analytical Characterization - Chemical	Integrated and Continuous Processing and Manufacturing	For Use in Drug Substance Manufacture
		Other
		Blinding of Comparator Drugs
Manufacturing and Analytical Characterization - Chemical	Manufacture of Clinical Supplies	Phase Appropriate GMP
		Other

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
		Clean Media
		Facility Design
		Media
		Media Fills
Manufacturing and Analytical Characterization - Chemical	Plant Engineering, Equipment and Maintenance	Modeling and Scheduling Multiproduct Batch Plants
		Modular Manufacturing
		Plant Incident Investigations
		Other
		Cleaning Validation
		Control of Impurity Formation
		In-Process Controls
		Process Analytical Technology and Parametric/Real-Time Release
		Process Modeling and Simulations
		Process Validation
Manufacturing and Analytical Characterization - Chemical	Process Design and Controls	QbD and Assessment of Process Parameters
		Robustness/CPV Continuous Process Verification
		Scale-Up/Process Transfers
		Statistical Process Controls and Six Sigma
		Use of Prior Knowledge and Risk-Based Approaches
		Other
		For Use in Drug Product Manufacture
Manufacturing and Analytical Characterization - Chemical	Single-Use and Disposable Systems	For Use in Drug Substance Manufacture
manadaming and Analytical Characterization Chemical	origic osc and Disposable dystems	Leachables and Extractables
		Other
		DP Handling
		In-Use Compatibility
		Nasal/Pulmonary
		Ocular
Francis Company   Dellarana   Dispusation	Administration	Otic
Formulation and Delivery - Biomolecular	Administration	Potent Modalities
		Sterility and Microbiology
		Strategies
		Transdermal
		Other
		Extended Release (Non-implant)
		Implants
		On Body Delivery Systems (OBDS)
		Other Routes of Administration - Ocular
Formulation and Delivery - Biomolecular	Drug Delivery	Other Routes of Administration - Otic
		Other Routes of Administration - Otto Other Routes of Administration - Transdermal and Topical
		Other Routes of Administration - Other
		Other Design Control
Formulation and Delivery - Biomolecular		Design Control
		Hardware
	Drug Delivery, Devices, and Drug Device	Human Factor Engineering
	brug benvery, bevices, and brug bevice	New Delivery Technologies
		Patient-Centric Development
		Software
		Cell Therapy
		Free Oligonucleotide
		Gene Therapy

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
Formulation and Delivery - Biomolecular	Formulation	Protein - Developability Assessment
		Protein - Excipients
		Protein - High-Throughput Screening
		Protein - Lyo
		Protein - Syringes
		Protein - Topics
		Protein - Other
		Vaccine/Tolerance Induction
		Other
Formulation and Delivery - Biomolecular	Primary Packaging	Compatibility
		Container Closure Integrity
		Extractables/Leachables
		New Materials
		Accelerated Approval Pathways
		Bioequivalence
		Biosimilars
		Innovative Technologies
		Inspections and GMPs
Formulation and Delivery - Biomolecular	Regulatory Considerations	Large Market Developments
		New Regulations and Guidances
		Risk Assessment Implementation
		Smaller Market Developments
		Stability Requirements
		(Sub)visible Particles
	Biopharmaceutics	BCS, DCS
		Bioequivalence (also Regulatory)
Formulation and Delivery - Chemical		Comparability Assessments
1 Official of and Benvery - Chemical		IVIVC
		Predictive Modeling
		Other
Formulation and Delivery - Chemical	Drug Delivery	Extended Release (Non-implant)
		Implants
		Other Routes of Administration - Ocular
		Other Routes of Administration - Otic
		Other Routes of Administration - Transdermal and Topical
		Other Routes of Administration - Other
		Nanoparticles
		Other
Formulation and Delivery - Chemical	Drug Delivery, Devices, and Drug Device	Design Control
		Hardware
		Human Factor Engineering
		New Delivery Technologies
		Patient-Centric Development
		Software
		Advanced Dissolution Testing
		Amorphous and Co-crystal Systems
		Bioavailability Enhancement
		Drug Substance Properties
		Excipients  Exact Pass Combinations
Formulation and Delivery Chamital	Formulation	Fixed Dose Combinations
Formulation and Delivery - Chemical	Formulation	Inhalation and Nasal

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
		Oral - Immediate Release
		Oral - Modified Release
		Parenterals
		Predictive Modeling
		Preformulation
		Special Populations
Formulation and Delivery - Chemical	Primary Packaging	Compatibility
		Container Closure Integrity
		Extractables/Leachables
		New Materials
Formulation and Delivery - Chemical	Regulatory Considerations	Accelerated Approval Pathways
		Bioequivalence
		Biosimilars
		Innovative Technologies
		Inspections and GMPs
		Large Market Developments
		New Regulations and Guidances
		Patient Focused Drug Development Guidelines
		Risk Assessment Implementation
		Smaller Market Developments
		Stability Requirements
		(Sub)visible Particles